Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review

BACKGROUND: Inclusion of productivity losses and gains in cost-effectiveness analyses for drugs is recommended by pharmacoeconomic guidelines in some countries and is considered optional in others. Often guidelines recommend analysis based on the payer perspective, but suggest that a supplemental an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuasa, Akira, Yonemoto, Naohiro, LoPresti, Michael, Ikeda, Shunya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790765/
https://www.ncbi.nlm.nih.gov/pubmed/33230613
http://dx.doi.org/10.1007/s40273-020-00986-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790765/
https://www.ncbi.nlm.nih.gov/pubmed/33230613
http://dx.doi.org/10.1007/s40273-020-00986-4

Ejemplares similares